LMR Partners LLP acquired a new stake in shares of Antares Pharma Inc. (NASDAQ:ATRS) during the second quarter, Holdings Channel reports. The firm acquired 282,738 shares of the specialty pharmaceutical company’s stock, valued at approximately $297,000.
Separately, Royce & Associates LP raised its stake in shares of Antares Pharma by 318.3% in the first quarter. Royce & Associates LP now owns 406,900 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 309,616 shares in the last quarter. Institutional investors and hedge funds own 36.34% of the company’s stock.
Shares of Antares Pharma Inc. (NASDAQ:ATRS) traded down 2.89% during trading on Friday, reaching $1.68. The company had a trading volume of 382,166 shares. The firm’s market capitalization is $260.50 million. Antares Pharma Inc. has a 1-year low of $0.67 and a 1-year high of $1.85. The firm has a 50-day moving average of $1.54 and a 200 day moving average of $1.14.
Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Antares Pharma had a negative net margin of 54.98% and a negative return on equity of 41.06%. The firm earned $12.20 million during the quarter, compared to the consensus estimate of $11 million. During the same quarter last year, the firm earned ($0.01) EPS. Analysts expect that Antares Pharma Inc. will post ($0.15) earnings per share for the current year.
Several analysts have recently commented on ATRS shares. Piper Jaffray Cos. reiterated an “overweight” rating and set a $2.00 price objective (down previously from $3.00) on shares of Antares Pharma in a report on Saturday, August 13th. Zacks Investment Research lowered Antares Pharma from a “buy” rating to a “hold” rating in a report on Tuesday.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma Inc. (NASDAQ:ATRS).
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.